Clinical Trial Update: A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 1/2 clinical trial evaluating the once-daily oral drug VT-464 in patients with castration-resistant prostate can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• VT-464

Snippet

Sponsor: Innocrin Pharmaceutical | Conditions: Castration-resistant Prostate Cancer, CRPC | Phase 1, Phase 2 | Status: COMPLETED